1. Home
  2. OI vs IMNM Comparison

OI vs IMNM Comparison

Compare OI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo O-I Glass Inc.

OI

O-I Glass Inc.

HOLD

Current Price

$15.43

Market Cap

2.0B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$19.49

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OI
IMNM
Founded
1903
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
OI
IMNM
Price
$15.43
$19.49
Analyst Decision
Buy
Strong Buy
Analyst Count
7
9
Target Price
$16.29
$26.89
AVG Volume (30 Days)
2.3M
1.1M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,455,000,000.00
$9,679,000.00
Revenue This Year
$1.41
N/A
Revenue Next Year
$1.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.23
$5.15
52 Week High
$16.04
$20.75

Technical Indicators

Market Signals
Indicator
OI
IMNM
Relative Strength Index (RSI) 73.59 58.01
Support Level $13.01 $18.87
Resistance Level $14.60 $20.80
Average True Range (ATR) 0.49 1.22
MACD 0.17 -0.03
Stochastic Oscillator 99.46 67.17

Price Performance

Historical Comparison
OI
IMNM

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: